Abbott Completes Acquisition of STARLIMS Technologies Abbott has completed its $123 million acquisition of STARLIMS Technology Ltd., a head in laboratory information administration systems. The acquisition provides Abbott with leading products and experience to build its position in laboratory informatics, an emerging and quickly growing field centered on helping to manage the increasing amount of data generated in laboratories eriacta100.org . STARLIMS’s advanced web-based applications help laboratories efficiently store, retrieve and evaluate data and are designed for a wide variety of laboratory conditions operating across numerous scientific, clinical and industrial disciplines. STARLIMS provides us access to innovative technologies and specialized expertise for our long-term technique in laboratory informatics, stated Edward L.
In the U87 GBM model, SCH 900105 administration led to finish tumor regressions after withdrawal of treatment also. Furthermore, several preclinical combination studies performed with SCH 900105 and additional targeted therapeutics, chemotherapies and anti-angiogenic brokers demonstrated additive efficacy in vivo. Predicated on the preclinical data and the Phase 1 results, AVEO offers initiated a Phase 2 trial of SCH 900105 in combination with gefitinib in individuals with non-little cell lung malignancy. Tony Mok, M.D., professor, department of scientific oncology, Prince of Wales Hospital, Hong Kong, and senior investigator of the Stage 2 trial commented, The preclinical outcomes combined with the results of the Phase 1 trial offer an encouraging system for further assessment of this candidate antibody.